The project, which has received funding from the prestigious European Research Council (ERC) through a Consolidator Grant, has already garnered significant international attention. By leveraging AI to enhance the design and understanding of antibody therapeutics, the researchers are opening new avenues for precision medicine.
A key aspect of the project is its collaboration with Genmab, a leading biotechnology company. This partnership underscores the translational potential of the research, demonstrating how academic discoveries can catalyze industrial innovation and contribute to the development of next-generation biologics.
“Greiff and Lund-Johansen embody the future of scientific innovation. Their interdisciplinary approach and global impact illustrate how frontier research can lead to novel treatment strategies and foster productive collaborations between academia and industry”, says Head of Innovation at Inven2, Halvard Grønlien, in the news story at the Inven2 website. Read the news story at the Inven2 website (in Norwegian)
Inven2 is the Tech transfer office for UiO and OUS.